Atrys Health Doubles Sales in 2022 and Seeks to Grow in Telediagnosis in Mexico

Atrys Health plans to continue its growth. One year after the debut of the Spanish company in the Continuous market, the group specialized in diagnostic services and precision medicine will close 2022 with a turnover of more than €200 million, which will mean doubling the sales of 2021, according to Santiago de Torres, president of Atrys Health, advances to PlantaDoce. In addition, the company will continue to grow in Mexico.

In 2021, its last year as a member of BME Growth, Atrys Health registered a turnover of €121 million, while the gross operating result (Ebitda) adjusted for non-recurring expenses stood at €24 million.

By 2023, the company is focusing its growth on Latin America, with special emphasis on Mexico and Colombia. In the Aztec country, the company chaired by De Torres hopes to enter the field of telediagnosis and does not rule out carrying out some corporate operations.

If you want to find more details about Atrys Health and read the latest financial news of the day, download for free our companion app. The Born2Invest mobile app, available for free for both Android and iOS devices, keeps its readers up to date with the most important market updates.

Atrys Health has recently acquired two clinics in Mexico

In Mexico, Atrys Health began operations in 2022 and has recently announced the opening of two new oncology clinics, a segment in which it is working in the country. The first of the facilities is located in Celaya (Guanajuato) and is specialized in cancer treatment.

The second center, located in the Puerta Polanco area (Mexico City), has specialized consultations, a genetics service, and a mixing center for the preparation of oncological drugs. Both complexes are added to the Cuidarte outpatient clinic in Mixcoac (Mexico City) owned by the Spanish company.

The company also seeks to grow in Colombia, increasing its services in the country. In 2019, Atrys Health purchased Teleradiología de Colombia Diagnóstico Digital Especializado, one of the largest companies in Colombia specializing in the provision of teleradiology services.

In Chile, the Spanish company acquired ChileRad at the end of 2022, a company specializing in teleradiology services. This incorporation allows Atrys Health to complete and consolidate its position in the Latin American country where it acquired Itms more than two years ago. “At the moment, our market share in Chile reaches 80%,” according to De Torres. Outside of Latin America, the diagnostic services group hopes to increase its presence in Anglo-Saxon countries, “preferably in Europe,” added the president of Atrys Health.

The company studies increasing its presence and is also looking for opportunities in Anglo-Saxon countries

Atrys Health provides diagnostic services and precision medical treatment, a pioneer in telemedicine and oncology, which has a team of more than 2,400 professionals and is present in Spain, Portugal, Switzerland, and Latin America.

The company structures its activity around three main business areas: high-precision medical-oncology and radiotherapy, diagnosis, which includes genetic diagnosis, pathology, and telemedicine, and preventive medicine, dedicated to prevention and training in the field of occupational risks and health, which serves more than one million workers through its network of 234 branches. The company was listed on the BME Growth in 2016, and on the Main Market of the Spanish Stock Exchange in February 2022.

__

(Featured image by Anna Shvets via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.